Novo Nordisk in India pricing
- Reporting shows about ten GLP‑1 generics launched in India at roughly $37–$85 per month, undercutting branded prices. (x.com) - Novo Nordisk is stressing brand trust while still holding U.S. patent protection for semaglutide through 2032. (x.com) - Analysts say Novo is also pursuing next‑gen semaglutide combos and oral pill formats to defend market share. (x.com)
Cheap semaglutide copies are reshaping Novo Nordisk’s playbook in India, where local drugmakers began launching lower-priced versions as patent protection ended in March. (business-standard.com) Semaglutide is the ingredient behind Ozempic, Wegovy and Rybelsus, medicines used for diabetes and obesity. India’s core patent expired on March 20, 2026, and about 10 drugmakers launched branded generics within days, with more than 50 brands expected over time. (business-standard.com) The new Indian prices are far below Novo’s earlier list prices. CNBC TV18 reported monthly treatment costs of about ₹1,800 to ₹4,200, versus roughly ₹11,000 before generic entry, while CNBC reported Sun Pharma launched one weekly injection at 750 rupees, or about 3,400 rupees a month. (cnbctv18.com) (cnbc.com) Novo has responded by cutting its own India prices. Business Today reported on March 31 that the company reduced starting-dose prices by 36% for Ozempic and 48% for Wegovy after generic launches accelerated. (businesstoday.in) India is an early test of what semaglutide competition can look like outside the United States. CNBC said India has about 100 million people living with diabetes, and Novo’s U.S. patent listings still show unexpired patents on Ozempic, where generic competition has not yet arrived. (cnbc.com) (novonordisk-us.com) Novo’s defense is not only price. CNBC reported the company is leaning on brand recognition and quality controls in a market where analysts expect dozens of rivals, but where manufacturing peptide drugs still requires tighter process controls than many standard pills. (cnbc.com) The company is also trying to move the market forward before copycats spread further. Business Standard reported Torrent has already announced an oral semaglutide product in India, and Novo said in February it signed a deal with Vivtex worth up to $2.1 billion to work on next-generation oral medicines for obesity and diabetes. (business-standard.com) (marketscreener.com) Novo’s own 2026 press releases also show the company pushing newer formats, including Wegovy HD in the U.S. in March and continued promotion of its Wegovy pill. India’s price war is happening as Novo tries to keep patients inside its franchise with new versions, not just the original injection. (novonordisk.com) For now, India is showing both sides of the semaglutide market at once: local companies are racing to make the drug cheaper, and Novo is racing to make its branded versions harder to replace. (cnbc.com)
